Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ONCY Stock Forecast 2025-2026
$1.04
Current Price
$108.70M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ONCY Price Targets
+571.8%
To High Target of $6.99
+303.9%
To Median Target of $4.20
+182.9%
To Low Target of $2.94
ONCY Price Momentum
+2.0%
1 Week Change
-14.0%
1 Month Change
+6.1%
1 Year Change
+14.3%
Year-to-Date Change
-31.1%
From 52W High of $1.51
+215.2%
From 52W Low of $0.33
📊 TOP ANALYST CALLS
Did ONCY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Oncolytics is one of their latest high-conviction picks.
Latest ONCY Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ONCY has a bullish consensus with a median price target of $4.20 (ranging from $2.94 to $6.99). The overall analyst rating is N/A (N/A/10). Currently trading at $1.04, the median forecast implies a 303.9% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ONCY Analyst Ratings
6
Buy
1
Hold
0
Sell
ONCY Price Target Range
Low
$2.94
Average
$4.20
High
$6.99
Current: $1.04
Latest ONCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ONCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 13, 2025 | Lake Street | Chad Messer | Buy | Initiates | $7.00 |
| May 21, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 16, 2025 | Jones Trading | Soumit Roy | Hold | Downgrade | $N/A |
| Mar 10, 2025 | RBC Capital | Douglas Miehm | Outperform | Maintains | $5.00 |
| Mar 10, 2025 | Maxim Group | Jason McCarthy | Buy | Maintains | $3.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Sep 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Apr 4, 2024 | Raymond James | Rahul Sarugaser | Outperform | Initiates | $3.00 |
| Mar 8, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jan 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jan 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Aug 16, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Jun 29, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Jun 23, 2023 | Canaccord Genuity | John Newman | Buy | Reiterates | $5.00 |
Oncolytics Biotech Inc. (ONCY) Competitors
The following stocks are similar to Oncolytics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Oncolytics Biotech Inc. (ONCY) Financial Data
Oncolytics Biotech Inc. has a market capitalization of $108.70M with a P/E ratio of -2.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -249.3%.
Valuation Metrics
Market Cap
$108.70M
Enterprise Value
$67.64M
P/E Ratio
-2.5x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+14.0%
Current Ratio
2.9x
Debt/Equity
14.6x
ROE
-249.3%
ROA
-74.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Oncolytics Biotech Inc. (ONCY) Business Model
About Oncolytics Biotech Inc.
What They Do
Develops innovative cancer therapeutics using viruses.
Business Model
The company focuses on developing pelareorep, an immuno-oncolytic virus delivered intravenously, which targets and destroys cancer cells. It generates funding through clinical trials, research collaborations, and potentially future product sales once therapies are commercialized.
Additional Information
Oncolytics Biotech Inc. addresses cancers that are resistant to traditional treatments and is positioned as a pioneer in viral-based cancer therapies. Its ongoing research and clinical trials aim to enhance patient outcomes in the oncology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Mr. Jared Kelly J.D., L.L.M.
Country
Canada
IPO Year
2018
Website
oncolyticsbiotech.comOncolytics Biotech Inc. (ONCY) Latest News & Analysis
Latest News
Quick Summary
Oncolytics Biotech reported a 30% overall response rate for pelareorep plus atezolizumab in ≥2L squamous cell anal carcinoma, with a median duration of response of 15.5 months. FDA discussions anticipated in Q1 2026.
Why It Matters
The promising results for pelareorep combined with atezolizumab in treating SCAC could lead to accelerated FDA approval, boosting Oncolytics Biotech's stock value and market position.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech Inc. has filed a Form F-4 with the SEC and plans a Special Meeting for shareholders to vote on changing its jurisdiction from Alberta, Canada, to Nevada, USA.
Why It Matters
Oncolytics Biotech's move to shift its jurisdiction to Nevada could enhance regulatory advantages, attract U.S. investors, and potentially increase its market valuation, impacting share prices.
Source: PRNewsWire
Market Sentiment:
Neutral
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
1 month ago
Quick Summary
Oncolytics Biotech Inc. has announced an update on the design of its planned registration-directed clinical trial for pelareorep in first-line pancreatic ductal adenocarcinoma.
Why It Matters
Oncolytics Biotech's update on its clinical trial for pancreatic cancer could influence stock performance, particularly if the trial shows promise for regulatory approval and market potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech reported progress in enrollment and U.S. site expansion for the GOBLET trial assessing pelareorep in gastrointestinal cancers, with data readouts expected soon.
Why It Matters
Enrollment progress and site expansion in the GOBLET trial indicate potential growth and advancements for Oncolytics Biotech, impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech's pelareorep shows prolonged survival in KRAS mutant mCRC, with median PFS and OS 2.5x better than current treatments. The company plans to advance regulatory pathways for further development.
Why It Matters
Pelareorep shows significant survival benefits in KRAS mutant mCRC, indicating potential market advantage. Positive data may boost Oncolytics' stock and attract investor interest in immunotherapy.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech reported favorable safety data for pelareorep, now studied in over 1,200 patients, including 300 with gastrointestinal cancers, indicating its potential as a platform therapy.
Why It Matters
Positive safety data and potential efficacy of pelareorep in gastrointestinal cancers can enhance investor confidence in Oncolytics Biotech's stock, indicating growth potential and market interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ONCY Stock
What is Oncolytics Biotech Inc.'s (ONCY) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Oncolytics Biotech Inc. (ONCY) has a median price target of $4.20. The highest price target is $6.99 and the lowest is $2.94.
Is ONCY stock a good investment in 2026?
According to current analyst ratings, ONCY has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ONCY stock?
Wall Street analysts predict ONCY stock could reach $4.20 in the next 12 months. This represents a 303.9% increase from the current price of $1.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oncolytics Biotech Inc.'s business model?
The company focuses on developing pelareorep, an immuno-oncolytic virus delivered intravenously, which targets and destroys cancer cells. It generates funding through clinical trials, research collaborations, and potentially future product sales once therapies are commercialized.
What is the highest forecasted price for ONCY Oncolytics Biotech Inc.?
The highest price target for ONCY is $6.99 from at , which represents a 571.8% increase from the current price of $1.04.
What is the lowest forecasted price for ONCY Oncolytics Biotech Inc.?
The lowest price target for ONCY is $2.94 from at , which represents a 182.9% increase from the current price of $1.04.
What is the overall ONCY consensus from analysts for Oncolytics Biotech Inc.?
The overall analyst consensus for ONCY is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.20.
How accurate are ONCY stock price projections?
Stock price projections, including those for Oncolytics Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 3:40 AM UTC